Rapid depletion of CD20+ B and T cells following ofatumumab therapy onset
Ofatumumab effectively depletes CD20<sup>+</sup> lymphocytes already after the first administration. This depletion affects not only B cells, but also a small proportion of T cells (CD3<sup>+</sup>CD20<sup>+</sup>), affirming the hypothesis that the anti-inflammatory effects of CD20<sup>+</sup> cell depletion might extend to the reduction of CD3<sup>+</sup>CD20<sup>+</sup> T lymphocytes.
Authors
- Thomas Skripuletz (ORCID: https://orcid.org/0000-0001-8550-335X)
- Tabea Seeliger (ORCID: https://orcid.org/0000-0002-6018-6826)
- Stefan Gingele (ORCID: https://orcid.org/0000-0002-6055-5695)
- Nora Möhn
- Julian Reza Kretschmer
- Sandra Nay (ORCID: https://orcid.org/0000-0002-4986-1181)
- Daria Tkachenko
- Dominica Ratuszny
- Philipp Schwenkenbecher (ORCID: https://orcid.org/0000-0002-1260-1650)
- Franz Felix Konen (ORCID: https://orcid.org/0000-0002-8609-5674)
- Lea Grote‐Levi
- Konstantin Fritz Jendretzky
- Martin W. Hümmert (ORCID: https://orcid.org/0000-0002-5928-2343)
- Roland Jacobs (ORCID: https://orcid.org/0000-0003-2942-7924)
- Anna Lena Streichert
Institutions
- Medizinische Hochschule Hannover (DE)
Publication Details
- Journal
- Multiple Sclerosis and Related Disorders
- Published
- 2024-09-14
- DOI
- https://doi.org/10.1016/j.msard.2024.105886
- Citations
- 5
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.12